Many of the tumor types that performed poorly in this analysis, for example melanoma and pancreatic adenocarcinoma, are characterized by highly recurrent point mutations (BRAF V600E for melanoma and KRAS activating mutations for pancreatic adenocarcinoma) that could be detected via high sensitivity targeted assays. Here, BRAF is linked to pancreatic adenocarcinoma.